Fig. 5From: Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndromeThe AMPK signaling pathway is activated in vitro and in vivo. A The AMPK signaling pathway was one of the four common signaling pathway upregulated by honokiol in PHCs and in the livers of HFD- and CDAHFD-fed mice. B The AMPK signaling was negatively associated with cell death-associated genes, immune response-associated genes, and lipid metabolism-associated genes in HFD-fed mouse livers. C Western blots of p-AMPKα, AMPKα, p-ACC, ACC, p-mTOR, mTOR, and CPT1α in PHCs stimulated with palmitic acid (PA) for 18 h at the indicated concentrations. n = 3 replicates. D Western blots of p-AMPKα, AMPKα, p-ACC, ACC, p-mTOR, mTOR, and CPT1α in the livers of HFD-fed mice treated with vehicle or honokiol. n = 5 mice per group. E Western blots of p-AMPKα, AMPKα, p-ACC, ACC, p-mTOR, mTOR, and CPT1α in the WAT of HFD-fed mice treated with CMC or honokiol. n = 5 mice per group. F Western blots of p-AMPKα, AMPKα, p-ACC, ACC, p-mTOR, mTOR, and CPT1α in the livers of CDAHFD-fed mice treated with vehicle or honokiol. n = 5 mice per group. G Western blots of p-AMPKα, AMPKα, p-ACC, ACC, p-mTOR, mTOR, and CPT1α in the livers of MCD-fed mice treated with vehicle or honokiol. n = 5 mice per groupBack to article page